IL6-inhibitors in treatment of SARS COVID19
DOI:
https://doi.org/10.15587/2519-4798.2022.258354Keywords:
COVID-19, IL-6 inhibitors, tocilizumab, respiratory failure, inflammation, monoclonal antibody, D-dimer, dexamethasone, mechanical ventilationAbstract
The aim of this study was to evaluate the clinical efficacy and safety of a two-dose approach in the administration of tocilizumab in patients with SARS COVID19
Material and methods. The study was carried out on the basis of the Odrex Medical House in 2000-2021. The total sample included 4,112 patients hospitalized in a specialized department with coronavirus pneumonia. Of this sample, 150 patients were prescribed tocilizumab at a dose of 8 mg/kg of patient weight, including 36 (24.0 %) cases when tocilizumab was administered in a two-dose regimen. In the case of a two-dose regimen, the second dose was administered no earlier than 24 hours after the first one.
All patients were examined according to the current clinical protocols. The hemogram, the content of CRP, ferritin, interleukin-6 were assessed. All patients received dexamethasone intramuscularly at a dose of at least 6 mg per day.
Statistical processing was carried out by methods of analysis of variance using the software Statistica 13.0.
Results. After the use of tocilizumab, the patients had a decrease in body temperature and a decrease in the need for oxygen support. At the same time, the normalization of indicators of the activity of the systemic inflammatory response was observed.
Mortality after the use of tocilizumab was 29.3 %; in all cases, the deaths had an extremely severe course of coronavirus infection and a significant comorbid background. There were no manifestations of anaphylaxis and cases of secondary infection after the appointment of tocilizumab.
Conclusions. The use of tocilizumab could significantly improve the condition of patients with SARS COVID19. There were no signs of anaphylaxis and cases of secondary infection after the administration of tocilizumab. In the absence of a pronounced clinical effect within 24 hours after the first dose of tocilizumab in patients with severe SARS COVID19, it is advisable to re-administer the drug (two-dose regimen)
References
- Han, F., Liu, Y., Mo, M., Chen, J., Wang, C., Yang, Y., Wu, J. (2021). Current treatment strategies for COVID 19 (Review). Molecular medicine reports, 24 (6). doi: http://doi.org/10.3892/mmr.2021.12498
- WHO Coronavirus (COVID-19) Dashboard. Available at: https://covid19.who.int
- Shah, M. D., Sumeh, A. S., Sheraz, M., Kavitha, M. S., Venmathi Maran, B. A., Rodrigues, K. F. (2021). A mini-review on the impact of COVID 19 on vital organs. Biomedicine & pharmacotherapy, 143. doi: http://doi.org/10.1016/j.biopha.2021.112158
- Muratova, T. M., Khramtsov, D. M., Vorokhta, Yu. M., Vikarenko, M. S., Dobush, I. V., Kozlova, G. G. et. al. (2021). Acute disorders of cerebral circulation in patients with COVID-19. Achievements of Clinical and Experimental Medicine, 2, 14–22. doi: http://doi.org/10.11603/1811-2471.2021.v.i2.12197
- Burger, A. L., Kaufmann, C. C., Jäger, B., Pogran, E., Ahmed, A., Wojta, J., Farhan, S., Huber, K. (2021). Direct cardiovascular complications and indirect collateral damage during the COVID-19 pandemic: A review. Wiener klinische Wochenschrift, 133 (23-24), 1289–1297. doi: http://doi.org/10.1007/s00508-021-01956-2
- Protokol «nadannia medychnoï dopomohy dlia likuvannia koronavirusnoï khvoroby (COVID-19) (2021). Nakaz Ministerstva okhorony zdorov’ia Ukrainy No. 762. 02.04.2020 (u redaktsii nakazu Ministerstva okhorony zdorov’ia Ukrainy No. 1979. 20.09.2021). Available at: https://moz.gov.ua/uploads/6/33091-dn_1979_20_09_2021_dod.pdf
- Klopfenstein, T., Gendrin, V., Kadiane-Oussou, N. J., Conrozier, T., Zayet, S. (2022). Tocilizumab in COVID-19 pneumonia: Practical proposals based on a narrative review of randomised trials. Reviews in medical virology, 32 (1), e2239. doi: http://doi.org/10.1002/rmv.2239
- Ascierto, P. A., Fu, B., Wei, H. (2021). IL-6 modulation for COVID-19: the right patients at the right time? Journal for immunotherapy of cancer, 9 (4), e002285. doi: http://doi.org/10.1136/jitc-2020-002285
- Kulanthaivel, S., Kaliberdenko, V. B., Balasundaram, K., Shterenshis, M. V., Scarpellini, E., Abenavoli, L. (2021). Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review. Reviews on Recent Clinical Trials, 16 (2), 138–145. doi: http://doi.org/10.2174/1574887115666200917110954
- Borovikov, V. P. (2016). Populiarnoe vvedenie v sovremennyi analiz dannykh i mashinnoe obuchenie na Statistica. Saint Petersburg, 354.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Serhii Shcherbakov, Hanna Mazurenko, Ihor Iovenko
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
